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Available clinical evidence suggests that the newer antipsychotics are similar to conventional 
antipsychotics for positive symptom control. It has been suggested that they may also be 
superior for negative symptoms and side effects, but the evidence for this is unclear (Duggan 
et al, 1999, Kennedy et al, 1999, Srisurapanont et al, 1999, Thornley et al, 1999, Tuunainen 
and Gilbody, 1999, Wahlbeck et al, 1999).  These differences if they exist, may lead to 
improvements in quality of life and patient satisfaction and subsequent rates of compliance 
with therapy.  If the latter occurs, there may also be improvements in the overall level of 
symptom control and rate of relapse.  Economic evaluations of risperidone suggest that these 
differences could lead to savings in the use of hospital inpatient care compared to 
conventional antipsychotics (Guest et al, 1996, Glennie, 1997).  
 
The available economic evidence suggests that the use of clozapine has the potential to 
improve the efficient use of health and social service resources in some patients (Revicki et 
al, 1990, Davies & Drummond, 1993, Meltzer et al, 1993, Aitchison & Kerwin, 1997, 
Glennie, 1997, Rosenheck et al, 1997).  All of these studies indicate that overall, clozapine is 
associated with lower rates of hospital inpatient admissions and lower duration of inpatient 
stay.  These are due to earlier discharge from the index inpatient admission and lower rates of 
relapse.  These differences in the use of inpatient care are sufficient to offset the additional 
costs of purchasing clozapine. 
 
However, the designs of all the economic studies raise several issues of concern, such as 
control for biases, sources of data and methods of data collection, measurement of outcomes, 
the type and dose regimes of comparator drugs.  In addition, the clinical and economic data 
for these evaluations were collected for a patient population with a long duration of illness 
and/or who are treatment resistant or intolerant of typical antipsychotic therapy.  It is not 
clear that these are applicable to people with early schizophrenia or those who have not had 
problems with previous antipsychotics. 
 
Patients currently categorised as treatment resistant or treatment intolerant are likely to have 
a long history of schizophrenia.  This is partly due to historical factors, such as the limited 
number of antipsychotics available, concerns about the safety of clozapine and the restricted 
use of expensive atypical antipsychotics.  These factors may be associated with a relatively 
poor quality of life and more intensive use of health care services in patients with a longer 
duration of illness.  Any improvements in clinical outcome as a result of a change in 
antipsychotic may also result in relatively important changes in health status and intensity of 
health service utilisation, compared to those with a recent diagnosis of schizophrenia.  In  Antipsychotic Medication for People With First Episode Schizophrenia 
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addition, there is some limited evidence that the use of services following entry to a clinical 
trial is related to the level of resource use prior to entry (Rosenheck et al, 1999). 
 
Furthermore, there is a trend to reduce reliance on inpatient or institutional care for people 
with acute or chronic mental illness.  The total number of commissioned hospital bed days 
for people with mental illness decreased from 14 million to 11.5 million between 1992-3 and 
1997-8 and the number of ward attendees fell from 124000 to 93000 (Department of Health, 
1998a).  Over the same period the number of daily available hospital beds for people with 
mental illness declined from 47000 to 37000, while the number of outpatient attendances rose 
from 1.8 million to 2.1 million (HPSS, 1998).  Creed et al (1997) suggest that approximately 
40% of people with acute episodes of mental illness (including schizophrenia) can be treated 
by attending psychiatric day hospitals rather then with hospital inpatient admissions.  
 
These factors may over estimate the likely value for money of the atypical antipsychotics, in 
cohorts of people with first episode schizophrenia in the current UK mental health service 
(Rosenheck et al, 1999). 
 
Given the constraints on health and social care budgets, purchasers and providers need to 
ensure that resources are used efficiently. A variety of guidelines and treatment protocols 
have been published, or developed for use at a local level to support decisions about the 
choice of antipsychotic for people with a first episode of schizophrenia.  In addition, there are 
wide variations in the availability and use of the atypical antipsychotics in the UK.  Current 
published literature is not sufficient to address all the economic issues of concern and there is 
a need for evaluation of the relative efficiency of clozapine and the new antipsychotics.  The 
NHS R&D HTA has funded primary research to assess the relative costs and utility of typical 
and atypical antipsychotics for people who are resistant to or intolerant of at least two 
antipsychotics.  However, the results of the research will not be available for at least 3 years. 
In addition, it is also important to assess the value of the new drugs in the context of 
alternative prescribing guidelines, and for people with a first episode of schizophrenia. This 
paper presents the results of secondary research to explore the potential economic impact of 
atypical antipsychotics for people in the context of current clinical guidelines. 
 
2.  METHODS  
 
2.1 Objectives 
The primary objective was to compare the potential economic impact of typical and atypical 
antipsychotics, for people with a first episode of schizophrenia for a number of different 




patients who were intolerant to or did not respond to the initial antipsychotic.  The second 
scenario explored the impact of specifying the sequence of antipsychotic therapies following 
withdrawal from the first. 
 
2.2 Comparators 
The antipsychotics included in the analysis were constrained to two typical antipsychotics: 
chlorpromazine and haloperidol and three atypical antipsychotics: risperidone, clozapine and 
olanzapine.  Other antipsychotics were excluded due to concerns about safety and lack of 
efficacy (eg Sertindole) when compared to typical antipsychotics, or relatively small market 
share in the UK (eg quetiapine, amisulpiride). 
 
2.3 Approach 
The study used the framework of economic evaluation to estimate the potential efficiency or 
value for money of the typical and newer atypical antipsychotics.  This included an 
assessment of the likely clinical and patient outcomes and associated health and social 
service resource use.   A decision analytic model was developed from existing clinical 
guidelines to compare the expected costs and outcomes associated with each of the therapies 
and estimate the range of uncertainty surrounding these results.   
 
2.4 Perspective 
The perspective of the analysis was constrained to that of the providers/funders of health and 
social care services and patients.  Whilst this did not extend to a full societal perspective, it 
did include those perspectives where the use of atypical antipsychotics is likely to have a 
major impact. 
 
2.5 Patient population 
To be consistent with the population targeted by current clinical guidelines (Conley and 
Buchanan, 1997, McEvoy et al, 1997, Lehman et al, 1998, Kerwin et al, 1999, Stubbs and 
Haw, 2000), the analysis was restricted to a consideration of the likely costs and outcomes 
for patients with a first episode of schizophrenia.  This allowed exploration of the future 
potential of the atypical antipsychotics in a mental health service that is itself subject to 
change. 
 
2.6 Time frame 
The analysis used a three year time frame to assess alternative prescribing strategies. The 
time frame of the model allows up to 3 switches of therapy within the first year, plus a 4
th, 
undefined, therapy for those patients who are intolerant of or resistant to three medication.    
For those patients who move to maintenance therapy, there is a small but significant annual 
risk of tardive dyskinesia.  The three year time frame of the model allows a patient  to try Antipsychotic Medication for People With First Episode Schizophrenia 
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three antipsychotics at annual intervals (the maximum number of antipsychotics with 
differential rates of estimated tardive dyskinesia).  It also allows the patient to complete one 
year of the final antipsychotic.    
 
2.7 Outcome measures 
The analysis uses one intermediate and two final outcomes.  First, the proportion of people 
who require one or more changes in therapy.  Secondly, the expected total direct costs of the 
resources used to provide health and social care services.  Thirdly, the benefits to patients in 
terms of expected quality adjusted life years (QALY’s).  For the latter measure, the analysis 
assumes no difference in survival over the time frame of the evaluation.  However it is 
assumed that differences in symptom control and side effect profiles will affect the utility 
associated with each of the comparators (Glennie, 1997, Rosenheck et al, 1998).  
 
2.8 Decision analytic model 
Figure 1 presents a decision path to illustrate the potential consequences associated with the 
initial decision to prescribe an antipsychotic medication for people with a first episode of 
schizophrenia.   The model starts at the point at which a person presents with a first episode 
of schizophrenia. The clinician and patient then have a choice of antipsychotic drug therapies 
for the treatment of the acute episode.  It is assumed that the option of no drug therapy is not 
applicable in this case (Thornley et al, 1999).  Whichever therapy is chosen, the range of 
possible events is assumed to be the same.  However, the probability of those events 
occurring may vary between  the alternative antipsychotics. 
 
Following initiation of antipsychotic therapy for first episode schizophrenia, there is a chance 
that the treatment will be acceptable to both patient and clinician or not acceptable (chance 
node A).   For those patients who find treatment acceptable, there may be associated adverse 
events, which are treatable and/or acceptable (chance node B).  If the patient has no adverse 
events or treatable adverse events, they are transferred to maintenance therapy.  Whilst on 
maintenance therapy the patient may relapse within the three year time frame (chance nodes 
C and D).  If the patient relapses, following acceptable treatment it is assumed that they will 
be treated for an acute episode, with the same antipsychotic.  Following each relapse there 
will be a chance that therapy is acceptable or not acceptable (chance node A).  For those 
patients continuing on maintenance therapy, there is a chance that they will have an adequate 
response to therapy or not.  Those with an adequate response are assumed to have mild 
symptoms, and those with an inadequate response to have moderate symptoms. 
 
If the initial therapy is not acceptable, this may be due to intolerance (adverse events which 
are not treatable or not acceptable), inadequate response or non compliance (chance node E).   5
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If the patient is intolerant to therapy, there will be a switch to an alternative antipsychotic.  
Following each switch in therapy there is a chance that the new treatment will be acceptable 
or not (chance node A). 
 
If the patient has an inadequate response to therapy which is unacceptable, there will be a 
switch to an alternative antipsychotic.   Following each switch in therapy there is a chance 
that the new treatment will be acceptable or not (chance node A). 
 
If the patient does not comply with therapy, for whatever reason, there is a chance that they 
will have a relapse.  If they relapse, there will be a switch in antipsychotic.  Following each 
switch in therapy there is a chance that the new treatment will be acceptable or not (chance 
node A).  If the patient does not relapse, it is assumed that there will be no change in 
treatment strategy. 
 
2.9 Analyses of data 
Probabilistic simulations were used to estimate the expected costs and outcomes associated 
with  each of the antipsychotics, and alternative guidelines or treatment protocols (Doubillet 
et al, 1985). To conduct the simulations, key variables were each assigned a central value 
(e.g. mean, best guess) and a distribution or spread around that measure (e.g. standard 
deviation, minimum or maximum).  The key variables, methods of estimation and sources of 
data are described in section 3. The simulation recalculated the results over a number of 
iterations.  For each iteration the value of the key variables was sampled at random from the 
distributions specified.  By repeating the calculations of expected costs and outcomes in this 
way a spread of estimates is obtained, which allow estimation of the mean expected costs and 
QALY’s and associated 95% confidence intervals.   
 
Two analyses were conducted using alternative distributional forms for the data.  For the 
first, the normal distribution was specified for the majority of the variables for the base case 
analyses.  A truncated form of the distribution was specified for the probability parameters, 
which were constrained to values between 0 and 1.  Resource use and unit cost variables 
were also constrained to values between the minimum and maximum possible for each item.  
For example, inpatient stay per year must be constrained to be equal to or greater than 0 days, 
but less than 366 days.  Where national statistics gave minimum and maximum values for 
variables these were used in preference to hypothetical constraints.  
 
The main advantage of the normal distribution is that it incorporates all the estimates of event 




normally distributed around the measure of central tendency.  There was some evidence that 
the input data were skewed, which could in principle, result in a type 1 error.   
 
To assess whether the distribution used would affect the results in terms of mean expected 
values, variance and statistical significance of differences in expected values, the second 
analysis used the triangular distribution. The main advantage of the triangular distribution is 
that it makes no assumptions about the distribution or spread of values around the most likely 
estimate of a parameter.  However, it may be inefficient in that it only uses three pieces of 
information.  For each variable these were the minimum and maximum values found, plus an 
estimate of the most likely value.  The most likely value was calculated as the mean of all 
estimates identified.  
 
The sampling method used was Monte Carlo, true expected value.  The simulation software 
used was @RISK, as an add on to MSOFFICE Excel v.7.0.  Every simulation requires 
sufficient iterations to ensure that each variable is sampled over the full distribution of values 
specified and the statistics generated are reliable.   As the number of iterations increases, the 
distribution for the outcomes is described in more detail and becomes more stable.  The 
amount of change in the percentile values, mean and standard deviation decreases with each 
subsequent iteration.  The number of iterations for each simulation were determined by the 
software, which halted the simulation when convergence at less than 1.5% in percentile 
values, mean and standard deviation was achieved.  
 
2.9.1 Simulated three year expected costs and QALY’s 
The analysis of expected costs and QALY’s associated with each of the antipsychotics was 




line therapies was not governed by pre-determined decision rules.  The expected costs and 
QALY’s of follow on therapy were estimated using a triangular distribution.  This requires 
three values, minimum, best guess and maximum.  The minimum and maximum were 
determined by the range of expected costs and QALY’s estimated by the model.  The best 
guess estimate was set as the median value of these variables.  
 
The first stage was to determine the costs of failure of 3
rd line therapy.  This was imputed by 
estimating the expected costs and quality adjusted life years associated with each of the 
antipsychotics when used as 3
rd line therapy, excluding follow on medication for those who 
found 3
rd line therapy unacceptable.  The median expected costs and QALY’s were used to 
proxy the expected costs and QALY’s of 4
th line therapy.  A triangular distribution was used, 
based on the minimum and maximum values found, with the median values used as the 
measure of central tendency. Antipsychotic Medication for People With First Episode Schizophrenia 
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In the second stage, the imputed total expected costs and QALY’s for follow on medication 
for patients who failed 2
nd line therapy were estimated. These were calculated as the expected 
costs and QALY’s of  3
rd line therapy (including the expected costs and QALY’s of 4
th line 
follow on medication and care). The imputed costs and benefits of 3
rd line medication for 
those patients who found the 2
nd line antipsychotic unacceptable, were estimated from the 
median values using a triangular distribution. 
 
The third stage was to calculate the expected costs and quality adjusted life years of follow 
on therapy for those patients who found the 1
st line antipsychotic unacceptable, which were 
calculated as for 2
nd line therapy.  
 
2.9.2 Simulated three year expected costs and QALY’s of alternative treatment protocols 
The simulation analysis was repeated to assess the relative impact on expected costs and 
QALY’s of 8 protocols specifying the sequence of antipsychotics from the first episode of 
schizophrenia.  The term typical antipsychotic refers to chlorpromazine or haloperidol, 
atypical antipsychotic refers to risperidone or olanzapine, and excludes clozapine.  The 
protocols are summarised as: 
1. Typical antipsychotic 1
st and 2
nd line, atypical antipsychotic 3
rd line, clozapine 4
th line; 
2. Typical antipsychotic 1
st and 2
nd line, clozapine 3
rd line, atypical antipsychotic 4
th line; 
3. Typical antipsychotic 1
st line, atypical antipsychotic 2




4. Typical antipsychotic 1
st line, atypical antipsychotic 2
nd line, clozapine 3
rd line, typical 
antipsychotic 4
th line; 
5. Typical antipsychotic 1
st line, atypical antipsychotic 2
nd line, clozapine 3
rd line, atypical 
antipsychotic 4
th line; 
6. Atypical antipsychotic 1
st and 2
nd line, clozapine 3
rd line, typical antipsychotic 4
th line; 
7. Lower dose typical antipsychotic 1
st line, atypical antipsychotic 2
nd line, atypical 
antipsychotic 3
rd line, clozapine 4
th line; 
8. Lower dose typical antipsychotic 1
st line, atypical antipsychotic 2





The expected costs and QALY’s for these protocols were estimated in three stages as above.  
In addition, each antipsychotic could not be used for more than one stage of therapy within 
the protocol.  For example, in protocol 1, if the first typical antipsychotic used was 
chlorpromazine, then the 2
nd line therapy was restricted to haloperidol. 




3. DATA AND VARIABLE ESTIMATION 
3.1 Sources of data 
The principle source of data was a review of published clinical and economic literature.  
Relevant literature was identified from a search of Medline, Econlit, Cinahl and the Cochrane 
library.  If a systematic review from the Cochrane Library was available, this was used as the 
principal source of clinical data.  The other clinical papers included in the review were used 
to supplement the data from the systematic reviews. Where a Cochrane review was used, the 
data for this analysis was derived from all the studies included in the Cochrane review, which 
used an active comparator.  Placebo controlled trials were excluded for this economic 
evaluation.  The general inclusion criteria for the Cochrane reviews are that the studies are 
randomised controlled trials (RCTs) with low (category A) to moderate bias (category B) 
(Cochrane Schizophrenia Group, 1999).   
 
Specific exclusion criteria for individual clinical papers to supplement the Cochrane 
systematic reviews were: trials with no active comparator, non RCTs, pharmacologic or 
pharmacokinetic studies, dosing/titration studies or studies which did not include final 
clinical outcomes in terms of symptom control or patient acceptability. Some papers which 
did not meet these criteria were included only if they contained information relevant to the 
estimation of economic endpoints in terms of resource use or costs.  There were relatively 
few economic publications, so all economic evaluations which included a comparison of the 
costs and outcomes of alternative treatments were included in the review. 
 
3.2 Variable estimation: probabilities of events 
The probability data for the model were drawn from a variety of sources, for heterogeneous 
populations.  In addition, many of the data for the probability of events were drawn from a 
number of clinical trials.  The variability in antipsychotic trial design, comparators, outcome 
measure and length of follow up is well documented (Thornley et al, 1999, Wahlbeck, 1999, 
Kennedy et al, 1999, Tuunainen et al, 1999).  This meant that the available data on event 
rates were not consistent or directly comparable across studies. Composite variables were 
defined to reduce variation in the outcome measures reported.  
 
Where more than one source of data was available the mean (standard deviation) probability 
values for the model were estimated as the average probability of an event weighted by the 
size of the trial. This gave more weight to larger trials: ∑(pti*nti)/ no. of trials. 
 
3.2.1 Probabilities of events: composite variables 
To reduce inconsistency due to differences in the measures of outcome and adverse events 
used in different trials and differences in the methods of reporting these data a number of 
composite variables were defined.  These also simplified the construction of the model and Antipsychotic Medication for People With First Episode Schizophrenia 
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analysis of the data.  These were clinical improvement, acceptability of treatment, 
intolerance, compliance and inadequate response.   
 
The definition of inadequate response was taken as that used by the systematic review or trial 
investigators. Adequate response or clinical improvement was estimated as 1- the probability 
of inadequate response.   
 
Acceptability of treatment was defined as the proportion of people able and willing to 
continue with the prescribed antipsychotic as maintenance therapy.  These people may have 
no adverse events associated with therapy, or adverse events which are tolerable or treatable.  
They may also have an inadequate response, but prefer to remain on allocated treatment.  
Acceptability of treatment was estimated from systematic review or clinical trial data on the 
number of people who remained in allocated therapy.  Unacceptable treatment was estimated 
as 1- the probability that treatment was acceptable. 
 
Intolerance, inadequate response and non compliance were then defined as unacceptable 
levels of these events which led to discontinuation of allocated therapy.  Intolerance was 
defined as events which mandated a switch in therapy because of: 
 
•  irreversible or life threatening consequences which could not be adequately treated (for 
instance neuroleptic malignant syndrome (NMS), tardive dyskinesia, agranulocytosis and 
hepatic dysfunction); 
 
•  a level of severity of adverse events which could not be adequately resolved with 
additional treatment. 
 
The conditional probability of intolerance, given unacceptable treatment was estimated as: 
 
[Pae - (Pae * Pat) + Ptd + Pnms + Pag + Phd] 
Pat 
Pae = the probability of adverse events which are not irreversible or life threatening; 
Pat = the probability that treatment is acceptable; 
Ptd = the probability of tardive dyskinesia; 
Pnms = the probability of neuroleptic malignant syndrome; 
Pag = the probability of agranulocytosis; 




This calculation ensures that adverse events which are not irreversible or life threatening are 
weighted by the acceptability of treatment and that there is no double counting.  It also 
ensures that events which are irreversible or life threatening are only represented in the 
intolerance branch of the model, and are not under estimated. 
 
Non compliance was defined as refusal to adhere to a treatment regime which had adequate 
symptom control.  In addition, depot therapy had either failed or was not an appropriate 
option.  The probability of non compliance was estimated from the literature.  The 
conditional probability of non compliance given unacceptable treatment was estimated as the 
probability of non compliance divided by the probability of unacceptable treatment. 
 
The definition of adequate and inadequate response to therapy used in clinical trials varied 
considerably.  Therefore inadequate response requiring a change in therapy was defined as a 
default variable.  The conditional probability of an inadequate response, given 
unacceptability of treatment was defined as 1 minus the conditional probability of intolerance 
minus the conditional probability of non compliance. 
 
3.2.2 Probabilities of events: Lower dose typical antipsychotics 
Descriptions of the maximum allowable dose of the typical antipsychotics were used to 
determine trials which used lower dose therapy only. Lower dose typical antipsychotic 
medication was defined as equal to or less than 12mg haloperidol per day or chlorpromazine 
equivalent. 
 
3.3 Variable estimation: costs of events 
The costs of events were estimated from measures of the health and social care service use 
associated with the events, multiplied by the unit costs or prices of those events.  Wherever 
possible, resource use was estimated from clinical guidelines or best practice.  In addition, it 
was assumed that the use of long stay residential or institutional care for first episode patients 
would be determined by the socio deomographic characteristics of the patients and severity 
of disease, rather than the choice of antipsychotic drug.  This implied the further assumption 
that the choice of antipsychotic would only affect the need for acute inpatient services for 
initiation of therapy, switch of antipsychotic and acute management of relapses.  In 
particular, the costs of long term maintenance therapy excluded the costs of long stay nursing 
home or residential care, since it was assumed that these would not be affected by the choice 
of drug in the patient population considered.  
 Antipsychotic Medication for People With First Episode Schizophrenia 
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These assumptions do not reflect the relative impact of the antipsychotics on the current 
cohort of patients with long standing schizophrenia and who may be treatment resistant or 
intolerant of therapy.  However, the assumptions are consistent with the objectives and 
patient group for this analysis. 
 
3.4 Variable estimation: quality adjusted life years 
Quality adjusted life years (QALY’s) were estimated as life years weighted by the utility of 
the health status experienced within the period of analysis.  It was assumed that all patients 
would survive for the full period of analysis (3 years).  This may overestimate the total 
survival and therefore QALY’s for each of the comparisons. There is no evidence of 
differences in survival for the antipsychotics included in this analysis, so is unlikely to affect 
relative differences in the estimates of expected QALY’s. However health status and health 
related quality of life would vary according to symptoms and adverse events.  It was assumed 
that all patients would have either mild symptoms or moderate to severe symptoms.  It was 
also assumed that adverse events and admission to hospital would incur a disutility (or 
negative utility).  Utility values between 0 and 1 were attached to mild symptoms and 
moderate to severe symptoms. 
 
4 RESULTS 
4.1 Probabilities of events 
The majority of the clinical trial data were for people with chronic schizophrenia.  It was not 
possible to estimate probabilities of events using data which were specific to a first episode 
population only.    There was considerable inconsistency in the measurement and reporting of 
events.  In particular, many of the reports did not include events which occurred in less than a 
pre-defined proportion of patients, or for which there was no statistically significant 
difference between comparators. 
 
This meant that the adverse events included in the analysis were restricted to those where 
data was available for all comparators, or were irreversible or life threatening.  These were 
EPS (excluding tardive dyskinesia), tardive dyskinesia, neuroleptic malignant syndrome, 
hepatic dysfunction and agranulocytosis.  It is likely that other events were indirectly 
included if they were severe enough to lead to discontinuation of therapy.  In addition, these 
were the main events with clearly defined management strategies.   
 
Table 1 presents the average or best guess estimates of the probabilities of events, (with 
standard deviations where appropriate), which were estimated from the raw data from the 
clinical trials and systematic reviews included in the analysis. The majority of data were 




reported the rates of specific events to estimate standard deviations or minimum and 
maximum values for tardive dyskinesia, neuroleptic malignant syndrome, hepatic dysfunction 
and agranulocytosis.  These events were not assigned a distribution in the model.   
 
Tables 2 and 3 present the derived probabilities of the events included in the model, for two 
alternative distributions of data. The data in Table 2 were derived from the mean value and 
standard deviation, assuming a truncated normal distribution, which was restricted to a 
minimum value of zero and a maximum value of 1.  It was assumed that the total number of 
patients within the included trials represented a sufficiently large sample to approximate a 
normal distribution.  However, the use of the normal distribution may bias the results and/or 
be inefficient if the data take an alternative distributional form. 
 
Table 3 presents the derived probabilities when a triangular distributional form was imposed.  
This was estimated from data on the weighted average or best guess, minimum and maximum 
values for events which were assigned a distribution.  The weighted average or best guess 
was assigned as the most likely value.  The direction of the skew of the data was determined 
by the most likely value in relation to the minimum and maximum values specified. There 
were differences in most of the values assigned to different events between the two 
distributional forms.  However, there was no consistent trend which affected the relative 
differences between the event rates assigned to each of the antipsychotics. 
 
4.2 Use of health and social care services  
Table 4 presents the estimated use of inpatient care from available economic evaluations of 
antipsychotic therapy. All of the studies were based on data for patients with a relatively long 
duration of schizophrenia, many of whom also had a history of long durations of inpatient 
care.  The average number of inpatient admissions ranges from less than 1 per year to 2 per 
year.  The average length of stay per year ranges from 25 to 365 days.  Many of these studies 
included patients with a long duration of illness and/or previous inpatient or residential and 
were not considered appropriate for the patient population included in this analysis.   
 
Table 5 presents the data for the model on use of health and social care services associated 
with initial therapy, maintenance therapy, management of relapses, switch in antipsychotic 
medications and treatment of adverse events.  The probability of inpatient admission for 
initiation of therapy was estimated from a recent trial of day and inpatient therapy for people 
with acute psychiatric illness (Creed et al, 1997). Nearly half of the patients in the trial had 
schizophrenia.  Antipsychotic Medication for People With First Episode Schizophrenia 
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The mean length of stay (and standard deviation) for people who had an inpatient admission 
was estimated from national data on the average length of stay for mental illness (CIPFA, 
1998).   A truncated normal distribution was applied.  This included the mean and standard 
deviation, with a minimum stay of 1 day and a maximum of 130 days stay.  The estimates of 
the probability of inpatient admission and average length of stay per admission were similar 
to those reported by a number of the studies reviewed in Table 4. 
 
The number of days per year for which community based services were required was 
calculated as 365 minus the length of inpatient stay for initiation/change of therapy and 
relapse. 
 
4.3 Unit costs of resources 
Table 6 presents the unit costs of resources.  The mean (standard deviation) costs of inpatient 
stay, day patient and outpatient visits were estimated from national hospital costs data 
(CIPFA, 1998).  They were assigned a normal truncated distribution. The costs of   
community services were taken from published data on the national average costs of health 
and social care services.  (Netten et al, 1998).  The costs of drug therapy were estimated from 
the British National Formulary, 1998. 
 
4.4 Utility and quality adjusted life years 
A number of studies have included quality of life measures such as the Quality of Life 
inventory, Heinrichs-Carpenter Quality of Life Scale or the Short Form - 36 for people with 
schizophrenia (Essock et al, 1996, Rosenheck et al, 1997, Mahmoud et al, 1998, Rosenheck 
et al, 1999).  Three studies indicated that there may be small improvements in the quality of 
life associated with clozapine and risperidone.  These were significant in favour of 
risperidone in one study (Mahmoud et al, 1998).  
 
Only three economic evaluations of antipsychotic therapy have used methods such as linear 
analogue, standard gamble and time-trade off techniques to estimate the preferences or utility 
associated with alternative health state scenarios for people with schizophrenia.  Rosenheck 
et al (1998) converted a Composite Health Index for Schizophrenia. This was used to 
estimate improvements in health state over a 12 month period. Converting these gains in 
health state to a 0-1 worst health-good health scale, gave a preference weighted improvement 
of 0.049 for clozapine and 0.027 for haloperidol.  In a double blind randomised clinical trial, 
this measure indicated a QALY gain of 2 for clozapine compared to haloperidol (Rosenheck, 
1999). 
 
 Chouinard et al, (1997) generated health state descriptions from data for 135 patients.  These 




functioning and extra pyramidal side effects.  The descriptions were clustered into mild, 
moderate and severe cases.  Psychiatric nurses were asked to imagine they had the health 
states described and rate them on a linear analogue scale.  The standard gamble technique 
was also used with the nurses to generate utility values for each of the health states.  The 
utility values for each health state were: mild 0.58-0.61, moderate 0.35-0.36 and severe 0.25-
0.29. These values were applied to patients in a trial comparing haloperidol and risperidone.  
Overall, patients taking risperidone were found to have a gain in utility of 0.08 over patients 
taking haloperidol.  This translated into a lifetime gain of 2.72-2.97 QALY’s (assuming equal 
life expectancy between treatment groups).   
 
The second evaluation (Glennie, 1997) estimated utility values for 7 patients with 
schizophrenia, using the standard gamble and rating scale techniques.  The patients were 
selected by health care professionals in one clinic and were judged as able to understand the 
scenarios presented and the process. These data were used to generate utility values for 
chlorpromazine, haloperidol, clozapine and risperidone, for mild and moderate-severe 
symptoms, and the disutility associated with EPS and hospitalisation.   
 
The values generated suggested a higher quality of life for each health state than those 
estimated by Chouinard et al (1997).  The differences between typical and atypical 
antipsychotics are also smaller (Table 7).  Overall, the utility estimates of Glennie (1997) 
appeared to be more conservative in favour of typical antipsychotics, and were the values 
used for this analysis.  However, the slightly higher utility value estimated for clozapine, 
compared to the alternative antipsychotics may favour any comparisons between clozapine 
and other atypical drugs.  The limited evidence from clinical trials suggest that clozapine and 
risperidone may be associated with higher quality of life and patient satisfaction than typical 
antipsychotics (Mahmoud et al, 1998, Rosenheck et al, 1998, Rosenheck et al, 1999).   
However, there is no trial based evidence of significant differences between the atypical 
antipsychotics in quality of life or patient satisfaction. 
 
4.5 Expected costs and outcomes: three years therapy 
Tables 8-9 present the simulated data for the expected three year costs and QALY’s of first 
treatment, by distributional form, for all patients, and patients who complete or fail initial 
therapy.  The costs and QALY’s for patients who fail initial therapy are estimated as the 
median values from data for all the antipsychotics.  Clozapine is not indicated for first or 
second line therapy and has been excluded from these analyses. The mean values and 95% 
confidence intervals are shown.  The confidence intervals would suggest that haloperidol and 
olanzapine are less effective (in terms of the likelihood of failing initial therapy and QALY’s) 
and more costly than chlorpromazine for both the normal and triangular distribution (i.e. the Antipsychotic Medication for People With First Episode Schizophrenia 
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confidence intervals for haloperidol and olanzapine do not overlap with those for 
chlorpromazine).  
 
These results imply that haloperidol and olanzapine are not efficient compared to 
chlorpromazine or risperidone.  This appears to be related to differences in the relative costs 
and QALY’s of patients who continue on initial therapy, and the proportion of patients who 
switch from the initial antipsychotic.  In particular, both haloperidol and olanzapine were 
associated with a high probability of relapse compared to the other antipsychotics, which 
increased the cost of patients who completed therapy.  The higher rate of relapse would also 
reduce the expected utility and QALY’s associated with these two treatments. 
 
Risperidone was associated with both higher expected costs and QALY’s than 
chlorpromazine. The additional cost/QALY gained by risperidone compared to 
chlorpromazine ranged from £34241 (triangular distribution) to £109935 (truncated normal 
distribution). 
 
The expected costs of patients who completed the three year time frame on the initial 
allocated therapy were lower than those who had to switch to at least one other therapy 
(Table 9).  The expected QALY’s for patients remaining on the initial  allocated therapy were 
higher than those who switched.  For those patients who switched allocated therapy, the 
expected costs and QALY’s were similar for each of the initial therapies.  However, for those 
patients who remained on allocated therapy, chlorpromazine dominated both haloperidol and 
olanzapine.  Risperidone was  associated with higher expected costs and QALY’s than 
haloperidol, and dominated olanzapine. 
 
Table 10 presents the expected costs and QALY’s for 2
nd, 3
rd and 4
th line therapy, by 
distributional form.  Clozapine was excluded from the analysis of 2
nd line treatment.  The 
percentage of patients completing or failing each line of therapy was assumed to be the same 
as for first line treatment.  The results of these analyses again suggest that haloperidol and 
olanzapine may not be efficient compared to risperidone, clozapine and chlorpromazine.   
 
They also suggest that risperidone and clozapine may be more effective than chlorpromazine 
but at an additional cost.  The expected cost/QALY gained by risperidone ranged from 
£59050 to £153600 using the truncated normal distribution and £15289 to £29437 using the 
triangular distribution.  The expected cost/QALY gained by clozapine compared to 
chlorpromazine ranged from £35689 to £47980 using the truncated normal distribution and 
£14054 to £15546 using the triangular distribution.  When clozapine is compared to 




distribution.  If the triangular distribution is used then clozapine is associated with higher 
expected costs and QALY’s compared to risperidone.  The expected cost/QALY gained 
ranges from £5314 to £22500.  
 
4.6 Expected costs and outcomes: treatment guidelines 
Tables 11 & 14 present the expected costs and QALY’s for alternative treatment guidelines, 
using the truncated normal distribution and triangular distributions.  The results for each 
distribution are summarised in Tables 12 & 15.  Tables 13 & 16 compare the guidelines in 
terms of incremental cost/QALY gained for each of the distributions.  
 
4.6.1 Choice of first line therapy 
For each of the guidelines which specify a typical antipsychotic as first line therapy, 
chlorpromazine as 1
st line treatment was consistently associated with lower expected costs 
and higher expected QALY’s than haloperidol used 1
st line (i.e. the 95% confidence intervals 
do not overlap).  In addition, lower dose typical antipsychotics were of lower cost or higher 
QALY’s than the average dose estimations.  Risperidone was associated with lower expected 
costs and higher expected QALY’s than olanzapine when used as first line therapy. 
 
Overall, the results suggest that lower dose chlorpromazine is associated with lower expected 
costs than risperidone or olanzapine.  In addition, lower dose chlorpromazine is associated 
with equivalent or higher expected QALY’s than olanzapine.  The expected QALY’s 
associated with lower dose chlorpromazine are lower than those associated with risperidone.  
The expected cost/QALY gained by risperidone ranges from £54755 (triangular distribution) 
to £663170 (triangular distribution).  The results suggest that risperidone is more efficient in 
terms of expected costs and QALY’s than haloperidol (low or average dose) as first line 
therapy.  Olanzapine may be a better choice than haloperidol (low or average dose) as first 
line therapy in some cases.   
 
The expected costs and QALY’s for average dose typical antipsychotics suggest that 
risperidone may be more efficient in terms of expected costs and QALY’s than haloperidol in 
all cases, and chlorpromazine in some cases.  Olanzapine may be preferred to haloperidol in 
some cases, but not chlorpromazine. 
 
4.6.2 Choice of second line therapy 
The results suggest that chlorpromazine is associated with lower expected costs and higher 
expected QALY’s than haloperidol and olanzapine as second line therapy (Table 17).   
Risperidone used as second line therapy dominates both haloperidol and olanzapine, in that it 
is associated with higher expected QALY’s at lower or equivalent expected cost.  If a Antipsychotic Medication for People With First Episode Schizophrenia 
 
18 
truncated normal distribution is used then chlorpromazine may be the preferred option 
compared to risperidone, in that the expected costs are lower, with only small differences in 
QALY’s.  However the results using a triangular distribution would suggest that risperidone 
may be preferred to chlorpromazine, with higher expected costs and QALY’s.  The expected 
cost/QALY gained by risperidone is between £25000 and £26000.  
 
4.6.3 Choice of third and fourth line therapy 
As with the previous analyses, haloperidol and olanzapine are associated with higher 
expected costs and QALY’s than the alternative antipsychotics.  Chlorpromazine is 
associated with lower expected costs and QALY’s than risperidone or clozapine.  Using the 
truncated normal distribution, the expected cost/QALY gained by risperidone compared to 
chlorpromazine ranges from £57800 to £66200 for third line therapy.  Clozapine dominates 
risperidone for fourth line therapy.  The expected cost/QALY gained by clozapine compared 
to chlorpromazine ranges from £31100 to £38000 for third line therapy and is £48000 for 
fourth line therapy.  Clozapine may be preferred to risperidone in terms of expected costs and 
QALY’s or expected costs/QALY gained compared to chlorpromazine. 
 
Using the triangular distribution the expected costs and QALY’s of chlorpromazine, 
risperidone and clozapine dominate those associated with haloperidol and olanzapine.  The 
expected costs and QALY’s of risperidone and clozapine are equivalent for most 
comparisons of third line therapy.  However, risperidone may be preferred to clozapine as 
fourth line therapy.  Both risperidone and clozapine are associated with relatively low 
expected costs/QALY gained when compared with chlorpromazine.  
 
5. CONCLUSIONS 
Overall, the data from the simulation analysis of three year expected costs and outcomes 
suggest that chlorpromazine, risperidone and clozapine (third and fourth line therapy only) 
were more efficient in terms of expected costs and QALY’s than haloperidol and olanzapine.   
 
The results also suggest that the expected costs and QALY’s associated with clozapine were 
always higher than for chlorpromazine.  The expected cost/QALY gained for clozapine 
ranged from £14000 to £48000, depending upon the distributional form and method of 
estimating probabilities of events used.  The data for risperidone was less clear. 
 
The results of the simulation to evaluate 6 alternative treatment protocols also suggested that 




th line therapy.  The 
results also suggested that risperidone was more efficient than chlorpromazine and 
haloperidol as 1
st and 2




haloperidol or chlorpromazine for 3
rd or 4
th line therapy and equivalent to or more efficient 
than risperidone.   
 
The analysis used a probabalistic simulation analysis to incorporate uncertainty in the 
estimates of event rates, resource use and unit costs.  Additional sensitivity analysis indicated 
that the results of the simulation  were sensitive to the distributional form used to derive 
estimates of probabilities, costs and utility values.  
 
However, there are a number of issues with the data and analyses which mean that the results 
are uncertain.  First, the analyses were exploratory in nature.  There were no hypotheses 
stated a priori.  This meant that there is a chance that some comparisons would yield 
apparently statistically significant results due to the large number of analyses conducted.  
Despite this, there were substantial similarities between the analyses in the results generated. 
 
Secondly, the differences in expected costs and QALY’s were small.  Analysis of the 95% 
confidence intervals suggests that many of the differences were statistically important.   
However, it is not clear that they would be clinically or economically relevant.  In particular 
it is not obvious that patients or clinicians would judge the very small differences in expected 
QALY’s to be important.   In addition, the exploratory nature of the analysis means that 
multiple comparisons of expected costs and QALY’s (with associated confidence intervals) 
have been made.  This means that although no formal tests of significance were used, some 
apparently statistically important differences may have occurred by chance rather than reflect 
true differences.  Both of these factors mean that there may be fewer relevant or statistically 
important differences than the analyses suggest. 
 
Thirdly, the data for olanzapine comes primarily from one main trial with limited follow up, a 
high rate of reported relapse, high rate of patient drop out and relatively less severe patients.  
It is possible that as new data become available, the estimates of effectiveness and cost 
effectiveness will be altered.  This trial may also have dominated the estimation of the 
probabilities of events for haloperidol, biasing the evaluation against haloperidol.  In 
addition, the probabilities of events for chlorpromazine (average and lower dose) and lower 
dose haloperidol were based on a relatively small number of trials and patients.  The data 
from these showed marked variation in results.  Again, this may mean that the evaluation of 
expected costs and outcomes for these drugs is not based on robust evidence. 
 
Fourthly, the analyses did not explicitly include the impact of a range of adverse events 
associated with antipsychotic medication.  It was assumed that these were included indirectly 
through two mechanisms.  First, side effects which were important to the patient or clinician Antipsychotic Medication for People With First Episode Schizophrenia 
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may be reflected in the rate of withdrawal from the trial.  Secondly, patients with mild 
symptoms were assigned utility values which varied by the type of antipsychotic.  Again it 
was assumed that these would reflect differences in the side effect profiles of the 
medications. 
 
Fifthly, the probabilities of events for average dose haloperidol and chlorpromazine were 
estimated from trials to compare these drugs to clozapine or other atypical antipsychotics.  It 
has been suggested that some of the trials may have used dose regimes for haloperidol or 
chlorpromazine which were higher than would be used in routine practice.  There is some 
evidence that higher doses may lead to worsening of symptoms (Bollini et al, 1994).   In 
addition, if the occurrence of adverse events are positively related to dose (Zimbroff et al, 
1997), the rates of some or all the adverse events for haloperidol in this analysis may be 
higher than those found in routine practice.  These two factors may have resulted in an under 
estimation of the expected QALY’s for chlorpromazine and haloperidol and an over 
estimation of expected costs. 
 
The main conclusions that can be drawn are first, that clozapine and risperidone, for the 
patient population assessed, may be more effective than typical antipsychotics and 
olanzapine, but at higher cost.  Not all of the additional cost of the drugs is offset by 
reductions in the use of services to manage people with schizophrenia.  Uncertainty about the 
validity of the clinical data for typical antipsychotics, the appropriate distributional form to 
be used and what is an acceptable cost/QALY mean that the analysis is unclear about 
whether these additional costs and benefits represent value for money.   
 
Secondly, despite the higher acquisition cost, the data and analyses suggest that clozapine is 
equivalent to or, in some cases more efficient than risperidone when used as 3
rd or 4
th line 
treatment, in terms of expected costs and QALY’s.   
 
Finally, a key determinant of the three year expected costs and QALY’s of treating first 
episode patients is likely to be the 1
st line therapy used.   
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Table 1  Probability of Events   
 
    Chlorpromazine
     Haloperidol
    Risperidone   Clozapine   Olanzapine     
   m e a n   ( r a n g e )
 2-5    mean  (range)
 2-5    mean  (range)
2,4,5,8 mean  (range)
 3,4,5 mean  (range)
 4,5,13
  
   A l l    L o w e r   d o s e   A l l    L o w e r   d o s e             
 
Inadequate response 0.73   0.48   0.64
   0.63
   0.48
    0.54
    0.59   
   (0.2-1)   (0.4-0.64)  (0.2-0.9) (0.2-0.9) (0.19-0.9)    (0.08-0.75)    (0.41-0.96)   
Adverse events                     
movement disorders  0.36   0.41   0.46
   0.45
   0.21
    0.29
    0.16   
   (0-0.68)   (0-0.68)   (0.14-1)   (0.27-1)   (0.07-0.59)   (0-0.75)    (0.03-0.29)   
 
tardive dyskinesia  0.05
6   0.05
6   0.05
   0.05
   0.003




7    0.005   0.005   0.005   0.005   0.00    0.00    0.00 
 
hepatic  dysfunction  0.06   0.06   0.06
   0.06
   0.00    0.02
12    n r    
 
agranulocytosis   0.00   0.00   0.00   0.00   0.00    0.02    nr   
 
Therapy not acceptable/ 
withdrawal   0.23   0.16   0.49
   0.46
   0.27    0.25
    0.60   
   (0.07-0.73)  (0.07-0.55)  (0-0.86)   (0-0.76)   (0-0.49)    (0-0.57)    (0.22-0.86)   
Relapse  
-with  therapy   0.13   0.14   0.42
   0.48
   0.27
10    0.08
    0.91   
   (0.05-0.52)  (0.05-0.52)  (0-0.97)   (0.38-0.63)  (0.08-0.45)
11   (00-0.29)   (0.08-0.91) 
- without therapy
7  0.75   0.75   0.75   0.75   0.75    0.75    0.75   
 
Non compliance,  
adequate therapy
7  0.09   0.09   0.09   0.09   0.09    0.09    0.09 
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Notes to Table 1 
 
1.   Estimated as weighted average of probability over trials included in analysis  
2.   Kennedy et al, 1999  
3.   Wahlbeck et al, 1999,  
4.   Tuunainen and Gilbody, 1999 
5.   Duggan et al, 1999 
6.   Assumed equal to haloperidol 
7.   Estimated value 
8.   Song et al, 1997 
9.   Esteinou and Grebb,  
10. No data reported, estimated from average rates for chlorpromazine (0.45) and clozapine (0.08), 
using assumption of uniform distribution 
11. Minimum and maximum values assumed 
12. Kane et al, 1988 
13. Tollefson et al, 1997 
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Table 2  Derived probability of events, truncated normal distribution 
  
    Chlorpromazine    Haloperidol    Risperidone Clozapine  Olanzapine   
 
    All    Lower  dose   All    Lower  dose       
Inadequate response   0.66  0.48    0.63  0.63    0.48   0.54   0.59 
 
Adverse events                    
- movement disorders   0.37 0.42     0.46 0.45     0.22   0.34   0.16 
-  tardive  dyskinesia   0.05  0.05    0.05  0.05    0.003   0.00   0.01 
-  NMS     0.005  0.005    0.005  0.005    0.00   0.00   0.00 
-  hepatic  dysfunction   0.06  0.06    0.06  0.06    0.00   0.02   0.00 
-  agranulocytosis   0.00  0.00    0.00  0.00    0.00   0.02   0.00 
 
Therapy not acceptable/ 
withdrawal    0.28  0.23    0.49  0.47    0.28   0.27   0.60   
 
Relapse  
-with  therapy    0.17  0.21    0.44  0.48    0.27   0.10   0.63   
-  without  therapy   0.75  0.75    0.75  0.75    0.75   0.75   0.75   
 
Non compliance,  




-non  compliance  0.08  0.09    0.07  0.07    0.11   0.09   0.11   
-  intolerance    0.37  0.46    0.42  0.42    0.28   0.37   0.19   
-  inadequate  response   0.56  0.46    0.51  0.51    0.61   0.54   0.70   
 
* Probabilities may not sum to 1 due to rounding error   29
Table 3  Derived probability of events, triangular distribution 
  
    Chlorpromazine    Haloperidol    Risperidone   Clozapine  Olanzapine 
  
    All    Lower  dose   All    Lower  dose 
Inadequate response   0.64  0.51    0.58  0.58    0.52    0.46   0.65 
Adverse events                     
- movement disorders   0.35  0.36    0.53  0.57    0.29    0.35   0.16 
-  tardive  dyskinesia   0.05  0.05    0.05  0.05    0.003    0.00   0.01 
-  NMS     0.005  0.005    0.005  0.005    0.00    0.00   0.00 
-  hepatic  dysfunction   0.06  0.06    0.06  0.06    0.00    0.02   0.00 
-  agranulocytosis   0.00  0.00    0.00  0.00    0.00    0.02   0.00 
Therapy not acceptable/ 
withdrawal    0.34  0.26    0.45  0.41    0.25    0.27   0.56 
Relapse  
-with  therapy    0.23  0.24    0.46  0.50    0.27    0.12   0.63 
-  without  therapy   0.75  0.75    0.75  0.75    0.75    0.75   0.75 
Non compliance,  
adequate therapy   0.09  0.09    0.09  0.09    0.09    0.09   0.09 
Therapy not acceptable
* 
-non  compliance  0.08  0.09    0.07  0.07    0.10    0.10   0.10 
-  intolerance    0.36  0.42    0.47  0.49    0.32    0.41   0.18 
-  inadequate  response   0.56  0.49    0.46  0.44    0.58    0.49   0.72 
 
 
* Probabilities may not sum to 1 due to rounding error 
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Table 4     Inpatient care associated with schizophrenia 
 
Study      Hospital  admissions   Average  length  of  stay 
         ( d a y s   p e r   y e a r )    
Addington et al, 1993 
(a) prior  to  risperidone  therapy   na     106 
(b) with  risperidone  therapy   na     85 
Aitchison and Kerwin, 1997     
(a) prior to clozapine therapy    2 per patient/year    130 
(b) with clozapine therapy    0.13 per patient/year    87.5  
Almond and O’Donnel, 1998 
(a) acute stay 
  initial therapy      60% patients admitted    27 days per admission 
 relapse     90%  patients  admitted   27  days  per  admission 
 relapse     10%  patients  admitted   81  days  per  admission 
(b) long stay        1.25% patients admitted   91 days per admission   
Davies and Drummond, 1993    
(a) re-admission      100% patients admitted   42 days per admission 
(b) long stay/residential care   
clozapine    82%  patients  admitted   365  days  per  admission 
standard neuroleptics    94% patients admitted    365 per admission 
Guest et al, 1996 
(a) prior  to  risperidone    na      172 
(b) 1
st  year  with  risperidone   na      119 
(c) 2
nd  year  with  risperidone   na      51 
Mahmoud et al, 1998 
(a) risperidone     1.25  per  patient/year    43 
(b) conventional  therapy  1.32  per  patient/year    43 
Meltzer et al, 1993 
(a) prior to clozapine therapy    1-1.5 per patient per year    64-133 
(b) with clozapine therapy    0.15-1 per patient per year    4-143 
Rosenheck et al, 1997 (inpatient psychiatric admissions) 
(a) clozapine     1.7      144 
(b) haloperidol     1.5      168 
Viale et al, 1997     
(a) prior  to  risperidone  therapy   0.47      25 
(b) with  risperidone  therapy   0.37      28 
UK national statistics 
CIPFA,  1998  (mental  illness)   na      45 
Department of health 1998b   
(a) Schizophrenia,  (F20-F29)   na      101 
(b) Mental  illness  (ICD-9,  710)   na      54 CHE Discussion Paper 178          31
Table 5   Resource use of events: model 
 
EVENT    Probability  Days    Total 
    
Initiation of 1
st therapy and treatment of acute episode or relapse      
Inpatient  admission    0.60   45.00  (sd:20)   27.00 
Daypatient  admission    0.40   24.00    10.00 
Antipsychotic  therapy    1.00   49.00    9.00 
      
      
Change antipsychotic      
Clozapine      
Daypatient  admission    1.00   14.00    14.00 
Antipsychotic  therapy    1.00   56.00    56.00 
Other antipsychotics      
Outpatient  visits   1.00   6.00    6.00 
Antipsychotic  therapy    1.00   56.00    56.00 
      
Additional treatment for adverse events/year      
EPS      
Anticholinergic     1.00   365.00    365.00 
Akathisia      
Beta  blocker     1.00   365.00    365.00 
Seizures      





Table 6   Unit costs of resources (1997 £) 
      
mean (sd)  minimum  maximum 
Hospital based services      
inpatient  stay  (per  day)      137.00  (42)  12.00   388.00 
outpatient visits (per visit)        81.00 (56)     
day  patient  (per  day)      56.61   37.00   57.00 
      
Community services (per day)       7.86   6.43   12.00 
      
Drugs (per patient day)      
Chlorpromazine       0.10   0.06   0.20 
Haloperidol       0.43   0.26   0.52 
Risperidone       3.90   2.57   5.15 
Clozapine       5.36   3.57   7.15 
Olanzapine       3.77   2.82   5.64 
anticholinergics       0.06    
beta adrenergic blocker (propranolol, 40mg bid)   0.01     
anticonvulsant, valproate, 1g/day      0.28   
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TABLE 7  UTILITY AND QUALITY ADJUSTED DAYS OF EVENTS  
 
E v e n t       Chlorpromazine  Haloperidol   Risperidone   Clozapine   Olanzapine 





Mild  symptoms    0.86  (0.77-0.95)  0.86(0.77-0.95)  0.89 (0.84-0.94)  0.91 (0.86-0.96)  0.89 (0.84-0.94) 
Moderate-severe  symptoms    0.82 (0.76-0.88)  0.82 (0.76-0.88) 0.82  (0.76-0.88) 0.82  (0.76-0.88) 0.82  (0.76-0.88)
  
Disutility of EPS or 
unacceptable  treatment   -0.07    -0.07    -0.07    -0.07    -0.07 
Disutility  of  inpatient  care   -0.07    -0.07    -0.07    -0.07    -0.07 
  
 
1. Glennie, 1997 
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TABLE 8  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S OF FIRST THERAPY: PER COHORT OF 1000 
PATIENTS 
 
Antipsychotic   Therapy change  Expected Cost    Expected QALY  Comparison     Cost/QALY 
   %  patients   mean  (95%CI)   mean  (95%CI) 
 
Triangular distribution 
    
chlorpromazine 
-  all  doses   34.32    17982170    2336   
   (33.66-34.99)   (17844285-18120055)(2334-2339) 
-  lower  dose   25.62    19921520    2300    Dominated  CPZ  not  relevant 
   (25.12-26.13)   (19739726-20103314)(2295-2304) 
haloperidol    
-  all  doses   44.45    20160470    2298      Dominated  CPZ  not  relevant 
   (43.64-45.27)   (19994590-20326350)(2295-2301) 
-  lower  dose   40.64    23944640    2199      Dominated  CPZ  not  relevant 
   (39.89-41.40)   (23727756-24161524)(2193-2206) 
risperidone   24.64    20653000    2414    CPZ    34241 
   (24.17-25.12)   (20507377-20798623)(2411-2416)       
olanzapine   54.65    22312200    2326    Dominated  CPZ  not  relevant 
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TABLE  9  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S: PER PATIENT COMPLETING OR  
SWITCHING THERAPY 
 
Antipsychotic     Expected  Cost  (mean,  95%CI)      Expected QALY (mean, 95%CI)   
    C o m p l e t e   t h e r a p y    S w i t c h   1
st therapy     Complete therapy  Switch 1
st therapy 
Truncated normal distribution 
Chlorpromazine     
- all doses      15627 (15369-15884)   21271 (20657-21886)   2.44 (2.41-2.47)  2.20 (2.13-2.26) 
- lower dose      16009 (15766-16253)   21337 (20705-21969)   2.46 (2.43-2.48)  2.19 (2.13-2.26) 
Haloperidol 
- all doses      18631 (18109-19153)   21093 (20572-21615)   2.39 (2.33-2.44)  2.21 (2.16-2.26) 
- lower dose      19031 (18528-19534)   21038 (20506-21570)   2.39 (2.33-2.44)  2.21 (2.16-2.27) 
Risperidone    20150  (19894-20405)   21229  (20718-21740)   2.50 (2.48-2.52)  2.23 (2.17-2.28) 




- all doses      15998 (15771-16225)   21779 (21345-22212)   2.41 (2.38-2.43)  2.20 (2.16-2.24) 
- lower dose      15966 (15770-16162)   31403 (30718-32088)   2.42 (2.41-2.44)  1.94 (1.90-1.98) 
Haloperidol 
- all doses      18909 (18537-19280)   21725 (21311-22138)   2.37 (2.34-2.41)  2.20 (2.16-2.25) 
- lower dose      19155 (18809-19501)   30939 (30294-31585)   2.36 (2.33-2.39)  1.96 (1.93-2.00) 
Risperidone    20307  (20099-20516)   21710  (21279-22140)   2.48 (2.46-2.49)  2.22 (2.18-2.26) 
Olanzapine      22989 (22570-23408)   21750 (21481-22019)   2.46 (2.42-2.49)  2.22 (2.19-2.24) 
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TABLE 10  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S OF ADDITIONAL THERAPY: PER PATIENT 
FAILING PREVIOUS THERAPY 
 
Antipsychotic     Expected  Cost  (mean,  95%CI)  Expected QALY (mean, 95%CI)  Incremental cost/QALY 
     
Truncated normal distribution 
Second line therapy 
Chlorpromazine    13646  (13432-13859)     2.26  (2.23-2.29)    
Haloperidol     16056  (15724-16388)     2.08  (2.04-2.13)   Dominated 
Risperidone     16718  (16516-16920)     2.28  (2.26-2.30)   £153600  vs  CPZ 
Olanzapine     18703  (18408-18997)     2.13  (2.10-2.16)   Dominated 
 
Third line therapy 
Chlorpromazine    13031  (12828-13235)     1.99  (1.97-2.02) 
Haloperidol     15951  (15609-16292)     1.78  (1.75-1.82)   Dominated 
Risperidone     16574  (16361-16788)     2.05  (2.03-2.07)   £59050  vs  CPZ 
Clozapine     16243  (16039-16446)     2.08  (2.06-2.10)   £35689  vs  CPZ 
Olanzapine     18992  (18697-19286)     1.78  (1.75-1.81)   Dominated 
 
Fourth line therapy 
Chlorpromazine    10776  (10691-10861)     1.60  (1.58-1.62)   
Haloperidol     14249  (14086-14412)     1.12  (1.09-1.15)   Dominated 
Risperidone     15912  (15801-16023)     1.68  (1.66-1.70)   £64200  vs  CPZ 
Clozapine     15574  (15506-15642)     1.70  (1.68-1.72)   £47980  vs  CPZ 
Olanzapine     19599  (19377-19821)     0.95  (0.93-0.96)   Dominated 
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TABLE 10  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S OF ADDITIONAL THERAPY: PER PATIENT 
FAILING PREVIOUS THERAPY 
 
Antipsychotic     Expected  Cost  (mean,  95%CI)  Expected QALY (mean, 95%CI)  Incremental cost/QALY 
 
Triangular distribution 
Second line therapy 
Chlorpromazine    14477  (14277-14676)    2.20  (2.18-2.23)     
Haloperidol     16651  (16382-16920)    2.12  (2.10-2.15)    Dominated 
Risperidone     16832  (16654-17011)    2.28  (2.26-2.30)    £29437  vs  CPZ 
Olanzapine     19113  (18868-19359)    2.13  (2.10-2.15)    Dominated 
 
Third line therapy 
Chlorpromazine    17570  (17314-17826)    2.09  (2.07-2.12) 
Haloperidol     20967  (20615-21319)    2.00  (1.97-2.03)    Dominated 
Risperidone     19025  (18809-19241)    2.15  (2.13-2.17)    £24250  vs  CPZ 
Clozapine     19397  (19166-19630) 2.22  (2.20-2.40)    £14054  vs  CPZ 
               £5314  vs  risperidone 
Olanzapine     25085  (24725-25445)    2.05  (2.03-2.07)    Dominated 
 
Fourth line therapy 
Chlorpromazine    11574  (11472-11676)    1.44  (1.42-1.46) 
Haloperidol     14804  (14633-14975)    1.20  (1.18-1.22)    Dominated 
Risperidone     15702  (15592-15812)    1.71  (1.70-1.72)    £15289  vs  CPZ 
Clozapine     15928  (15851-16004)    1.72  (1.70-1.74)    £15550  vs  CPZ 
               £22500  vs  risperidone 
Olanzapine     19702  (19486-19918)    1.03  (1.01-1.05)    Dominated 
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TABLE  11  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRUNCATED NORMAL DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY   
      mean  (95%CI)     mean  (95%CI)   
 
1.  Typical, typical, atypical, clozapine 
(a) Chlor’zine, hal., risp., cloz.  17312380  (17146606-17478154)   2298  (2290-2306)   
(b) Chlor’zine, hal., olanz., cloz.   17520510  (17372242-17668778)   2277  (2269-2285)   
(c) Hal., chlor’zine, risp., cloz.  18591970  (18386521-18797419)   2247  (2239-2255)   
(d) Hal., chlor’zine, olanz., cloz.   18802200  (18632165-18972235)   2232  (2224-2240)   
            
2.  Typical, typical, clozapine, atypical 
(a) Chlor’zine, hal., cloz., risp.  17347900  (17173853-17521947)   2289  (2280-2298)   
(b) Chlor’zine, hal., cloz., olanz.   17573540  (17400548-17746532)   2272  (2262-2281)   
(c) Hal., chlor’zine, cloz., risp.  18484450  (18285586-18683314)   2265  (2257-2273)   
(d) Hal., chlor’zine, cloz., olanz.   18459120  (18258174-18660066)   2238  (2228-2247)   
 
3.  Typical, atypical, atypical, clozapine        
(a) Chlor’zine, risp., olanz., cloz.   17475160  (17312058-17638262)   2365  (2358-2371)   
(b) Chlor’zine, olanz., risp., cloz.   17871550  (17711665-18031435)   2329  (2323-2336)   
(c) Hal., risp., olanz., cloz.     20381310  (20174928-20587692)   2289  (2281-2296)   
(d) Hal., olanz., risp., cloz.     21174570  (20976831-21372309)   2229  (2221-2238)   
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TABLE  11  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRUNCATED NORMAL DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY   
      mean  (95%CI)     mean  (95%CI) 
 
4.  Typical, atypical, clozapine, typical 
(a) Chlor’zine, risp., cloz., hal.    17590420 (17399038-17781802)    2369 (2362-2376)   
(b) Chlor’zine, olanz., cloz., hal.   17704610  (17497650-17911570)   2326  (2317-2334)   
(c) Hal., risp., cloz., chlor’zine.    20097030 (19874636-20319424)    2307 (2300-2315)   
(d) Hal., olanz., cloz., chlor’zine   20569910  (20330631-20809189)   2211  (2200-2222)   
               
               
5.  Typical, atypical, clozapine, atypical 
(a) Chlor’zine, risp., cloz., olanz.    17409010 (17249765-17568255)    2360 (2354-2366)   
(b) Chlor’zine, olanz., cloz., risp.   18024500  (17867894-18181106)   2329  (2322-2336)   
(c) Hal., risp., cloz., olanz.     20324950  (20128612-20521288)   2284  (2277-2291)   
(d) Hal., olanz., cloz., risp.     21083060  (20882353-21283767)   2230  (2221-2238)   
 
6.  Atypical, atypical, clozapine, typical 
(a) Risp., olanz., cloz., chlor’zine   20893250  (20720656-21065844)   2375  (2368-2381)   
(b) Olanz., risp., cloz., chlor’zine   21997490  (21799135-22195845)   2315  (2306-2324)   
(c) Risp., olanz., cloz., hal.      21024620 (20871119-21178121)    2375 (2369-2381)   
(d)  Olanz., risp., cloz., hal.    22106220  (21934678-22277762)   2326  (2318-2334)   
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TABLE  11  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRUNCATED NORMAL DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY   
      mean  (95%CI)     mean  (95%CI) 
 
 
   
7. Lower dose typical, atypical, atypical, clozapine        
(a) Chlor’zine, risp., olanz., cloz.   17643240  (17470744-17815736)   2391  (2384-2397)    
(b) Chlor’zine, olanz., risp., cloz.   18112900  (17934687-18291113)   2365  (2358-2372)   
(c) Hal., risp., olanz., cloz.     20582760  (20392089-20773431)   2291  (2284-2298)   
(d) Hal., olanz., risp., cloz.     21575460  (21365952-21784968)   2239  (2230-2248)   
  
8. Lower dose typical, atypical, clozapine, atypical 
(a) Chlor’zine, risp., cloz., olanz.    17496610 (17317783-17675437)    2381 (2374-2389)   
(b)  Chlor’zine, olanz., cloz., risp.   18041710  (17860908-18222512)   2351  (2344-2359)   
(c) Hal., risp., cloz., olanz.     20333050  (20122891-20543209)   2287  (2279-2295)   
(d) Hal., olanz., cloz., risp.     21362870  (21147150-21578590)   2235  (2226-2245)   
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TABLE  12  SUMMARY OF SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 
PATIENTS: BY TREATMENT GUIDELINE, TRUNCATED NORMAL DISTRIBUTION 
 
Guideline      Expected  Cost     Expected QALY    95% CI overlap* 
      m e a n        m e a n      C o s t s    Q A L Y ’ s  
 
 
Guidelines 1-5, 7, 8 
•  chlorpromazine 1
st  line    17252360-18112900     2272-2391    NO   NO 
•  haloperidol 1
st  line    18459120-21575460     2211-2307    NO   NO 
•  chlorpromazine vs haloperidol 1
st  l i n e             N O    N O  
Guidelines  1  &  2      
•  chlorpromazine 1
st  line    17312380-17573540     2272-2298    YES   YES 
•  haloperidol,1
st  line  18459120-18802200     2232-2265    YES   NO 
Guidelines 3 & 5 
•  chlorpromazine 1
st  line    17409010-18024500     2329-2365    YES   YES 
•  haloperidol, 1
st  line    20324950-21174570     2229-2289    YES   YES 
Guideline 4 
•  chlorpromazine 1
st  line    17590420-17704610     2326-2369    YES   NO 
•  haloperidol, 1
st  line    20097030-20569910     2211-2307    NO   NO 
Guideline 6 
•  risperidone 1
st  line     20893250-21024520     2375     YES   YES 
•  olanzapine 1
st  line     21997490-22106220     2315-2326    YES   YES 
•  risperidone vs olanzapine 1
st  l i n e              N O    N O  
Guidelines 7 & 8 
•  chlorpromazine 1
st  line    17496610-18112900     2351-2391    YES   YES 
•  haloperidol, 1
st  line    20333050-21575460     2235-2291    YES   YES 
 
TABLE 13  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES, TRUNCATED NORMAL DISTRIBUTION 
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Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
Guidelines 1 & 2 versus guidelines 3 & 5 
•  chlorpromazine 1
st  line        861-18038     guidelines  3  &  5 
•  haloperidol, 1
st  line        27704-96868     guidelines  1  &  2 
 
Guidelines 1 & 2 versus guideline 4 
•  chlorpromazine 1
st  line        174-14008     guideline  4 
•  haloperidol, 1
st line, 1c, 2c, 1d, 2d versus 4c        17264-38395        guideline 4 c 
•  haloperidol, 1
st line, 1c, 2c, 1d, 2d versus 4d        not relevant        guideline 1c, 2c, 1d, 2d 
 
Guidelines 1 & 2 versus guideline 6 
•  risperidone 1
st line versus chlorpromazine 1
st  line    32230-48211     guideline  6a,  6c 
•  olanzapine 1
st line versus chlorpromazine 1
st  line   83938-275594     guideline  1a,  3a,  1b,  3b 
•  risperidone 1
st line versus haloperidol 1
st  line     14623-23092     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  1c,  2c    44484-70261     unclear 
•  olanzapine 1
st line versus haloperidol 1
st  line,  1d,  2d    35149-45953     guideline  6b,  6d 
 
Guidelines 1 & 2 versus guidelines 7 & 8 
•  chlorpromazine 1
st  line        1616-13761     guidelines  7a,  8a,  7b,  8b 
•  haloperidol 1
st  line,  1c        43527-45245     guidelines  7c,  8c 
•  haloperidol 1
st  line,  7d,  8d     not  relevant     guidelines  1c,  1d 
 
 
TABLE 13  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES, TRUNCATED NORMAL DISTRIBUTION 
 
Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
Guideline 4 versus guidelines 3 & 5 
•  chlorpromazine 1
st  line        not  relevant     equivalent Antipsychotic Medication for People with First Episode Schizophrenia  42 
•  haloperidol 1
st  line      not  relevant     guideline  4  c  &  4d 
 
Guideline 4 versus guideline 6 
•  risperidone 1
st line versus chlorpromazine 1
st  line    65074-572367     guideline  4a,  4b 
•  olanzapine 1
st line versus chlorpromazine 1
st  line   not  relevant     guideline  4a,  4b 
•  risperidone 1
st line versus haloperidol 1
st  line     1972-13641     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  4c     105747-237558    guideline  4c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  4d     13359-13728     guideline  6b,  6d 
 
Guideline 4 versus guidelines 7 & 8 
•  chlorpromazine 1
st  line        2401-13484     guideline  7a,  8a,  7b,  8b 
•  haloperidol 1
st  line,  4c  versus  7c,  8c      not  relevant     guideline  4  c 
•  haloperidol 1
st  line,  4d  versus  7d,  8d      33040-35912     guideline  7d,  8d 
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TABLE 13  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES, TRUNCATED NORMAL DISTRIBUTION 
 
Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
 
Guideline 6 versus guideline 3 & 5 
•  risperidone1
st line versus  chlorpromazine 1
st  line    62364-354946     guideline  3a,  5a,  3b,  5b 
•  olanzapine 1
st line versus chlorpromazine 1
st line      not relevant        guideline 3a, 5a, 3b, 5b 
•  risperidone 1
st line versus haloperidol 1
st  line,  3c,  5c    5953-7689     guideline  6a,  6c 
•  risperidone 1
st line versus haloperidol 1
st  line,  3d,  5d    not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  3c,  5c    42411-62161     unclear 
•  olanzapine 1
st line versus haloperidol 1
st  line,  1d,  2d    9569-10658     guideline  6b,  6d 
 
Guideline 6 versus guideline 7 & 8 
•  risperidone 1
st line versus  
chlorpromazine 1
st  line,  7a,  8a,  7b      not  relevant     guideline  7a,  8a,  7b 
•  risperidone 1
st line versus chlorpromazine 1
st  line,  8b    118814-124288    guideline  8b 
•  olanzpine 1
st line versus chlorpromazine 1
st  line     not  relevant     guideline  7a,  8a,  7b,  8b 
•  risperidone 1
st line versus haloperidol 1
st  line,  7c,  8c    3696-7859     guideline  6a,  6c 
•  risperidone 1
st line versus haloperidol 1
st  line,  7d,  8d    not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
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TABLE  14  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRIANGULAR DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY     
      mean  (95%CI)     mean  (95%CI)   
 
1.  Typical, typical, atypical, clozapine 
(a) Chlor’zine, hal., risp., cloz.  20488210  (20277470-20698950)   2210  (2202-2217)   
(b) Chlor’zine, hal., olanz., cloz.   20450810  (20235049-20666571)   2217  (2209-2224)   
(c) Hal., chlor’zine, risp., cloz.  23062060  (22802328-23321792)   2184  (2177-2191)   
(d) Hal., chlor’zine, olanz., cloz.   23107690  (22850041-23365339)   2177  (2169-2185)   
            
2.  Typical, typical, clozapine, atypical 
(a) Chlor’zine, hal., cloz., risp.  20252300  (20034825-20469775)   2204  (2196-2212)   
(b) Chlor’zine, hal., cloz., olanz.   20231020  (20035084-20426956)   2212  (2205-2218)   
(c) Hal., chlor’zine, cloz., risp.  23021850  (22758217-23285483)   2193  (2186-2201)   
(d) Hal., chlor’zine, cloz., olanz.   22822150  (22585733-23058567)   2181  (2174-2188)   
 
3.  Typical, atypical, atypical, clozapine        
(a) Chlor’zine, risp., olanz., cloz.   20887550  (20669050-21106050)   2307  (2301-2312)   
(b) Chlor’zine, olanz., risp., cloz.   21024140  (20802433-21245847)   2252  (2246-2258)   
(c) Hal., risp., olanz., cloz.     23756410  (23500903-24011917)   2249  (2242-2255)   
(d) Hal., olanz., risp., cloz.     24279740  (24016550-24542930)   2179  (2170-2187)   
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TABLE  14  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRIANGULAR DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY   
      mean  (95%CI)     mean  (95%CI) 
 
4.  Typical, atypical, clozapine, typical 
(a) Chlor’zine, risp., cloz., hal.    20748010 (20522917-20973103)    2314 (2308-2319)   
(b) Chlor’zine, olanz., cloz., hal.   21038060  (20803675-21272445)   2257  (2251-2264)   
(c) Hal., risp., cloz., chlor’zine.    23887890 (23621629-24154151)    2269 (2263-2275)   
(d) Hal., olanz., cloz., chlor’zine   24160070  (23877586-24442554)   2193  (2184-2201)   
               
               
5.  Typical, atypical, clozapine, atypical 
(a) Chlor’zine, risp., cloz., olanz.    20441890 (20218382-20665398)    2318 (2313-2323)   
(b) Chlor’zine, olanz., cloz., risp.   21096480  (20870549-21322411)   2253  (2247-2259)   
(c) Hal., risp., cloz., olanz.     23611710  (23341015-23882405)   2269  (2263-2275)   
(d) Hal., olanz., cloz., risp.     24306150  (24044908-24567392)   2179  (2171-2186)   
 
6.  Atypical, atypical, clozapine, typical 
(a) Risp., olanz., cloz., chlor’zine   22911030  (22679844-23142216)   2350  (2344-2356)   
(b) Olanz., risp., cloz., chlor’zine   26994180  (26662205-27326155)   2296  (2288-2305)   
(c) Risp., olanz., cloz., hal.      22961460 (22757089-23165831)    2351 (2345-2357)   
(d)  Olanz., risp., cloz., hal.    26839930  (26544676-27135184)   2284  (2276-2292)   
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TABLE  14  SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER COHORT OF 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRIANGULAR DISTRIBUTION 
 
Guideline      Expected  Cost    Expected  QALY   
      mean  (95%CI)     mean  (95%CI) 
 
 
   
7. Lower dose typical, atypical, atypical, clozapine        
(a) Chlor’zine, risp., olanz., cloz.   19902400  (19697110-20107690)   2339  (2334-2343)    
(b) Chlor’zine, olanz., risp., cloz.   19895190  (19702302-20088078)   2295  (2289-2300)   
(c) Hal., risp., olanz., cloz.     23773980  (23517663-24030297)   2257  (2251-2263)   
(d) Hal., olanz., risp., cloz.     23967000  (23725732-24208268)   2187  (2180-2194)   
  
8. Lower dose typical, atypical, clozapine, atypical 
(a) Chlor’zine, risp., cloz., olanz.    19595180 (19392337-19798023)    2345 (2340-2350)   
(b)  Chlor’zine, olanz., cloz., risp.   19927810  (19724477-20131143)   2304  (2299-2310)   
(c) Hal., risp., cloz., olanz.     23489940  (23231551-23748329)   2267  (2261-2273)   
(d) Hal., olanz., cloz., risp.     23913110  (23663915-24162305)   2195  (2188-2202)   
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TABLE  15  SUMMARY OF SIMULATED THREE YEAR EXPECTED COSTS (£) AND QALY’S PER 1000 PATIENTS: BY 
TREATMENT GUIDELINE, TRIANGULAR DISTRIBUTION 
 
Guideline      Expected  Cost     Expected QALY    95% CI overlap* 
      m e a n        m e a n      C o s t s    Q A L Y ’ s  
 
 
Guidelines 1-5, 7, 8 
•  chlorpromazine 1
st  line    19595180-21096480     2204-2345    NO   NO 
•  haloperidol 1
st  line    22822150-24306159     2177-2269    NO   NO 
•  chlorpromazine vs haloperidol 1
st  l i n e             N O    N O  
Guidelines  1  &  2      
•  chlorpromazine 1
st  line    20231020-20488210     2204-2217    YES   YES 
•  haloperidol1
st  line     22822150-23107690     2177-2193    YES   YES 
Guidelines 3 & 5 
•  chlorpromazine 1
st  line    20441890-21096480     2252-2318    NO   NO 
•  haloperidol 1
st  line  23611710-24306159     2179-2269    NO   NO 
Guideline 4 
•  chlorpromazine 1
st  line    20748010-21038060     2257-2314    YES   NO 
•  haloperidol 1
st  line  23887890-24160070     2193-2269    NO   NO 
Guideline 6 
•  risperidone 1
st  line     22911030-22961460     2350-2351    YES   YES 
•  olanzapine 1
st  line     26839930-26994180     2284-2296    YES   YES 
•  risperidone vs olanzapine 1
st  l i n e              N O    N O  
Guidelines 7 & 8 
•  chlorpromazine 1
st  line    19595180-19927810     2295-2345    YES   NO 
•  haloperidol 1
st  line  23489940-23967000     2187-2267    YES   NO 
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TABLE 16  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES: TRIANGULAR DISTRIBUTION 
 
Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
Guidelines 1 & 2 versus guidelines 3 & 5 
•  chlorpromazine 1
st  line        1663-21109     guidelines  3  &  5 
•  haloperidol1
st  line,  1c,  2c        7761-10682     guidelines  3  &  5 
•  haloperidol 1
st line, 1d, 2d versus 3d, 5d         not  relevant     guidelines  1  &  2 
•  haloperidol 1
st  line,  1d,  2d  versus  3c,  5c      8972-9010     guidelines  3  &  5 
 
Guidelines 1 & 2 versus guideline 4 
•  chlorpromazine 1
st  line        2498-17934     guideline  4 
•  haloperidol 1
st line, 1c, 2c, 1d, 2d versus 4c        8480-12111        guideline 4 c 
•  haloperidol 1
st line, 1c, 2c, 1d, 2d versus 4d        not relevant        guideline 1c, 2c, 1d, 2d 
 
Guidelines 1 & 2 versus guideline 6 
•  risperidone1
st line versus  chlorpromazine 1
st  line    17306-19643     guideline  6a,  6c 
•  olanzapine 1
st line versus chlorpromazine 1
st  line   73281-95360     guideline  1a,  3a,  1b,  3b 
•  risperidone1
st line versus  haloperidol 1
st  line     not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line     32660-41957     guideline  6b,  6d 
 
Guidelines 1 & 2 versus guidelines 7 & 8 
•  chlorpromazine 1
st  line        not  relevant     guidelines  7a,  8a,  7b,  8b 
•  haloperidol1
st line, 1, 2 versus 7c, 8c          6325-9752        guidelines 7c, 8c 
•  haloperidol 1
st line, 1, 2 versus 7d, 8d          not relevant        guidelines 1d, 2d 
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TABLE 16  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES: TRIANGULAR DISTRIBUTION 
 
Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
Guideline 4 versus guidelines 3 & 5 
•  chlorpromazine 1
st  line        not  relevant     equivalent 
•  haloperidol 1
st  line      not  relevant     equivalent 
 
Guideline 4 versus guideline 6 
•  risperidone 1
st line versus chlorpromazine 1
st  line,  4a    59823-60084     guideline  4a 
•  risperidone1
st line versus  chlorpromazine 1
st  line,  4b    20139-20462     guideline  6a,  6c 
•  olanzapine 1
st line versus chlorpromazine 1
st  line   152721-214884    guideline  4a,  4b 
•  risperidone 1
st line versus haloperidol 1
st  line     not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  4c     115048-196803    guideline  4c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  4d     27516-29449     guideline  6b,  6d 
 
Guideline 4 versus guidelines 7 & 8 
•  chlorpromazine 1
st  line        not  relevant     guideline  7a,  8a,  7b,  8b 
•  haloperidol 1
st  line,  4c  versus  7c,  8c      not  relevant     equivalent 
•  haloperidol 1
st  line,  4d  versus  7d,  8d      not  relevant     equivalent 
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TABLE 16  EXPECTED COST/QALY GAINED OF ALTERNATIVE GUIDELINES: TRIANGULAR DISTRIBUTION  
 
Comparison          Incremental expected    Preferred guideline 
          c o s t / Q A L Y  
 
Guideline 6 versus guideline 3 & 5 
•  risperidone1
st line versus  chlorpromazine 1
st line, 3a, 3b, 5b    18707-47134        guideline 6a, 6c 
•  risperidone 1
st line versus chlorpromazine 1
st  line,  5b    76351-77161     guideline  5a 
•  olanzapine 1
st line versus chlorpromazine 1
st line      not relevant        guideline 3a, 5a, 3b, 5b 
•  risperidone 1
st line versus haloperidol 1
st  line     not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  3c,  5c    68889-215215     guideline  3c,  5c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  3d,  5d    22975-24383     guideline  6b,  6d 
 
Guideline 6 versus guideline 7 & 8 
•  risperidone1
st line versus  chlorpromazine 1
st  line       54755-663170     guideline  7a,  8a 
•  olanzpine 1
st line versus chlorpromazine 1
st  line     not  relevant     guideline  7a,  8a,  7b,  8b 
•  risperidone1
st line versus  haloperidol 1
st  line     not  relevant     guideline  6a,  6c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  7c,  8c    82569-197058     guideline  7c,  8c 
•  olanzapine 1
st line versus haloperidol 1
st  line,  7d,  8d    27772-32886     guideline  6b,  6d 
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TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Truncated normal distribution      
2
nd line therapy 
     
1. Chlorpromazine followed by 
a) risperidone, clozapine  13461 (13218-13704)   2.26 (2.22-2.30)    Equivalent to 1c, 1d 
b) olanzapine, clozapine  14238 (13988-14488)   2.22 (2.19-2.25)    Dominated by 1a, 1c, 1d 
c) clozapine, risperidone  13607 (13402-13812)   2.32 (2.29-2.35)    Equivalent to 1a, 1d 
d) clozapine, olanzapine  13725 (13497-13953)   2.23 (2.20-2.26)    Equivalent to 1a, 1c 
 
2. Haloperidol followed by 
a) risperidone, clozapine  16599 (16178-17020)   2.25 (2.20-2.30)    } 
b) olanzapine, clozapine  17528 (17138-17918)   2.13 (2.09-2.17)    } 
c) clozapine, risperidone  16854 (16520-17188)   2.21 (2.17-2.25)    }Dominated by 1, chlorpromazine 
d) clozapine, olanzapine  17299 (16923-17675)   2.13 (2.08-2.17)    } 
 
3. Risperidone followed by 
a) olanzapine, clozapine  17468 (17235-17701)   2.28 (2.26-2.30)    versus 1b, = £53833 
b) clozapine, haloperidol  16793 (16554-17032)   2.32 (2.30-2.35)   }Dominates  4,  olanzapine 
c) clozapine, chlorpromazine 16328 (16128-16528)   2.32 (2.30-2.34)    } 
d) clozapine, olanzapine  17159 (16926-17392)   2.27 (2.24-2.29)    Dominated by 1, chlorpromazine CHE Discussion Paper 178          53
TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Truncated normal distribution 
2
nd line therapy 
   
4. Olanzapine followed by 
a) risperidone, clozapine  19104 (18733-19475)   2.27 (2.23-2.31)    } Dominated by 1, chlorpromazine 
b) clozapine haloperidol  18450 (18077-18822)   2.16 (2.12-2.20)    } Dominated by 3b, risperidone 
c) clozapine, chlorpromazine 17890 (17598-18182)   2.21 (2.18-2.24)    } Dominated by 3b, risperidone 
d) clozapine, risperidone  18860 (18553-19167)   2.26 (2.23-2.29)    } Dominated by 1, chlorpromazine 
 
3
rd line therapy 
1. Chlorpromazine followed by 
a) haloperidol    12784  (12571-12997)   1.92  (1.90-1.95)    Dominated by 1b, 1c  
b) risperidone    13031  (12826-13236)   2.07  (2.04-2.09)    Equivalent 1c  
c) clozapine      13077 (12872-13281)   2.09 (2.06-2.11)    Equivalent 1b  
d) olanzapine      14339 (14128-14549)   1.86 (1.84-1.88)    Dominated by 1a, 1b, 1c  
 
2. Haloperidol followed by 
a) chlorpromazine    14134 (13856-14412)   1.91 (1.88-1.94)    } 
b) risperidone    16434  (16110-16758)   1.90  (1.86-1.94)   } 
c) clozapine      16307 (15979-16635)   1.94 (1.90-1.98)    } Dominated by 1, chlorpromazine 
d) olanzapine    18323  (17985-18661)   1.58  (1.55-1.61)   } 
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TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Truncated normal distribution 
3
rd line therapy 
   
3. Risperidone followed by 
a) chlorpromazine    15298 (15117-15479)   2.07 (2.05-2.09)    Dominated by 4a, clozapine 
b) haloperidol    16422  (16203-16641)   1.96  (1.94-1.98)   Dominated by 1, chlorpromazine, 4 clozapine 
c) clozapine      16388 (16189-16587)   2.14 (2.12-2.16)    versus 1c = £66220 
d) olanzapine    17805  (17593-18017)   1.92  (1.90-1.94)    versus 1d = £57767, dominated by 4 clozapine 
 
4. Clozapine followed by 
a) chlorpromazine    15218 (15049-15387)   2.12 (2.10-2.14)    Dominates 3a, risperidone 
b) haloperidol    16067  (15862-16272)   2.01  (1.99-2.03)    versus 1a = £36478 
c) risperidone    16447  (16244-16650)   2.16 (2.14-2.18)    versus 1b = £37956 
d) olanzapine      17134 (16935-17333)   1.95 (1.93-1.97)    versus 1d = £31056 
 
5. Olanzapine followed by 
a) chlorpromazine    16127 (15879-16375)   1.90 (1.87-1.93)    } 
b) haloperidol     18445 (18129-18761)   1.60 (1.57-1.63)    }Dominated by 1, chlorpromazine 
c) risperidone    19138  (18836-19440)   1.94  (1.92-1.97)   } 
d) clozapine    19144  (18848-19440)   1.91  (1.88-1.94)   } 
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TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
 
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Truncated normal distribution 
4
th line therapy 
1.  Chlorpromazine    10776 (10691-10861)   1.60 (1.58-1.62)     
2.  Haloperidol    14249  (14086-14412)   1.12  (1.09-1.15)    Dominated by 1, chlorpromazine 
3.  Risperidone    15912 (15801-16023)   1.68 (1.66-1.70)    Dominated by 4, clozapine 
4.  Clozapine      15574 (15506-15642)   1.70 (1.68-1.72)    versus 1 = £47980 
5.  Olanzapine     19599 (19377-19821)   0.95 (0.93-0.96)    Dominated by 1, chlorpromazine 
 
Triangular distribution      
2
nd line therapy      
 
1. Chlorpromazine followed by 
a) risperidone, clozapine  14355 (14172-14538)   2.18 (2.16-2.20)    } 
b) olanzapine, clozapine  14393 (14207-14579)  2.19  (2.17-2.21)   }Equivalent 
c) clozapine, risperidone  14322 (14137-14507)   2.18 (2.16-2.20)    } 
d) clozapine, olanzapine  14385 (14196-14574)   2.18 (2.16-2.20)    } 
 
2. Haloperidol followed by 
a) risperidone, clozapine  16555 (16291-16819)   2.12 (2.09-2.15)    } 
b) olanzapine, clozapine  16829 (16576-17082)   2.15 (2.12-2.18)    } Dominated by 1, chlorpromazine 
c) clozapine, risperidone  16617 (16359-16875)   2.13 (2.10-2.16)    } 
d) clozapine, olanzapine  16651 (16393-16909)   2.13 (2.10-2.16)    } Antipsychotic Medication for People with First Episode Schizophrenia  56 
TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Triangular distribution      
2
nd line therapy  
 
3. Risperidone followed by 
a) olanzapine, clozapine  16964 (16780-17112)   2.29 (2.27-2.31)    versus 1b = £25710 
b) clozapine, haloperidol  17062 (16900-17224)   2.31 (2.29-2.33)   }Dominates  4,  olanzapine 
c) clozapine, chlorpromazine 16946 (16777-17115)   2.28 (2.26-2.30)    } 
d) clozapine, olanzapine  16902 (16737-17067)   2.28 (2.26-2.30)    versus 1d = £25170 
 
4. Olanzapine followed by 
a) risperidone, clozapine  19099 (18873-19325)   2.14 (2.11-2.16)    } 
b) clozapine haloperidol  19128 (18898-19358)   2.13 (2.11-2.15)    } Dominated by 1, chlorpromazine 
c) clozapine, chlorpromazine 19085 (18851-19318)   2.13 (2.11-2.15)    } 
d) clozapine, risperidone  18900 (18673-19127)   2.11 (2.09-2.13)    } 
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TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Triangular distribution    
3
rd line therapy 
 
1. Chlorpromazine followed by 
a) haloperidol    16776  (16527-17024)   1.93 (1.91-1.95)    Dominated by 1b 
b) risperidone    17256  (17003-17509)   2.09  (2.07-2.11)   Equivalent  1c 
c) clozapine      17570 (17314-17826)   2.08 (2.06-2.10)    versus 1a = £5293 
d) olanzapine      17436 (17182-17690)   2.00 (1.98-2.02)    Dominated 1b, 1c 
 
2. Haloperidol followed by 
a) chlorpromazine    19426 (19105-19747)   2.00 (1.97-2.03)    } 
b) risperidone    20683  (20346-21020)   2.01  (1.98-2.04)    } Dominated by 1, chlorpromazine 
c) clozapine    20967  (20614-21318)   2.00  (1.97-2.03)   } 
d) olanzapine    21081  (20723-21439)   1.92  (1.89-1.95)   } 
 
3. Risperidone followed by 
a) chlorpromazine    18254 (18039-18469)   2.15 (2.13-2.17)    Dominates 5a, olanzapine 
b) haloperidol     18486 (18272-18700)   2.05 (2.03-2.07)    versus 1a= £14250 
c) clozapine      19025 (18809-19241)   2.15 (2.13-2.17)    versus 1c= £20786 
d) olanzapine    19332  (19104-19560)   2.12  (2.10-2.14)   versus  1d=  £15800 
 Antipsychotic Medication for People with First Episode Schizophrenia  58 
TABLE 17  EXPECTED COSTS (£) AND QALY’S PER PATIENT FAILING THERAPY OF 2
ND, 3
RD,  AND 4
TH LINE DRUGS: BY 
TREATMENT GUIDELINE 
            
Therapy     Expected costs    Expected QALY’s   Net expected cost/QALY 
 
Triangular distribution    
3
rd line therapy 
 
4. Clozapine followed by 
a) chlorpromazine    18864 (18637-19091)   2.22 (2.20-2.24)    versus 3a = £8714 
b) haloperidol     18825 (18601-19049)   2.08 (2.06-2.10)    versus 1a= £13660 
c) risperidone    19408  (19171-19645)   2.21  (2.19-2.23)   versus  1b=  £17933 
d) olanzapine    19874  (19633-20114)   2.15  (2.14-2.17)   versus  1d=  £16253 
 
5. Olanzapine followed by 
a) chlorpromazine    23418 (23063-23773)   2.05 (2.03-2.07)    } 
b) haloperidol    23603  (23260-23945)   1.80  (1.78-1.82)    } Dominated by 1, chlorpromazine 
c) risperidone    24390  (24037-24742)   2.01  (1.99-2.03)   } 
d) clozapine    25085  (24725-25445)   2.02  (2.00-2.04)   } 
 
4
th line therapy 
1.  Chlorpromazine    11574 (11473-11676)   1.44 (1.42-1.46) 
2.  Haloperidol    14804  (14633-14975)   1.20  (1.18-1.22)    Dominated by 1, chlorpromazine 
3.  Risperidone    15702 (15592-15812)   1.71 (1.70-1.72)    versus1 = £15289 
4.  Clozapine    15928  (15851-16003)   1.72  (1.70-1.74)    Dominated by 3, risperidone 
5.  Olanzapine     19702 (19486-19918)   1.03 (1.02-1.05)    Dominated by 1, chlorpromazine 
 
 